Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marinus Pharmaceuticals, Inc.

http://marinuspharma.com/

Latest From Marinus Pharmaceuticals, Inc.

Rare Genetic Epilepsy Responsive To Marinus's Ganaxolone

Marinus Pharmaceuticals has transformed its finances and the prospects for its R&D pipeline over the past 12 months, and has just reported positive top-line results from the Phase III MARIGOLD study of its lead compound, ganaxolone.

Clinical Trials Neurology

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.

Financing ImmunoOncology

Marinus Charts The Way Forward For Ganaxolone Amid Business Challenges

Phase II results for Marinus’s ganaxolone in postpartum depression are a mixed bag, but the US biotech sees potential in this and other neurological indications, probably with partners.

Neurology Clinical Trials

Pipeline Watch – Updates From EULAR, EHA and ECNP

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Nanotechnology, Chips, etc.
UsernamePublicRestriction

Register